5 Key Takeaways

• 1

  The FDA has approved clinical trials for genetically modified pig kidney transplants in patients with end-stage renal disease, starting in 2025.

• 2

  United Therapeutics and eGenesis will conduct trials to evaluate the long-term viability and immunogenic compatibility of xenotransplantation.

• 3

  United Therapeutics plans to enroll 6 patients initially, expanding to 50 if early safety and efficacy endpoints are met.

• 4

  eGenesis will start with three patients and increase enrollment in a staggered manner, monitoring health outcomes for 24 weeks post-transplant.

• 5

  Ethical concerns include informed consent for dialysis patients and potential zoonotic pathogen transmission risks associated with xenotransplantation.